Lifeboat Foundation

I do luv this.

New porject looks to turn a bandage into an mHealth sensor for PAD treatment.

Need to share this with a few folks researching glaucoma disease and treatment/ mutation reversal.

Elderly are frequently hospitalized due to their age-associated organ degeneration, the presence of co-morbidities, and their susceptibility to adverse insults. Alterations in functional status often occur during hospitalization, and the degree of functional decline can parallel the severity of illnesses. For older persons, gauging their pre-morbid and in-hospital functional status facilitates treatment planning and potentially functional restoration^1,2,3. While the identification of risk factors or markers of poor pre-morbid and in-hospital functional status may help facilitate this process, this area remains under-researched to date. Factors associated with functional decline in the hospitalized elderly include the types of morbidities and the reasons for their admission. Indeed, elderly with chronic kidney disease (CKD) are more likely to exhibit functional decline, beginning from the earlier stage of CKD to end-stage renal disease (ESRD)^4,5; functional dependency also predisposes individuals with CKD and ESRD to recurrent hospitalization and higher mortality.

Albuminuria and proteinuria, as the staging criteria for CKD in the most recent version of Kidney Disease Improving Global Outcomes (KDIGO) CKD guidelines, are both well-established predictors of subsequent renal function decline. There is increasing awareness that albuminuria and proteinuria have an independent role in the prediction of adverse outcomes apart from the baseline renal function. As explained above, although CKD is associated with poor functional status, it is still unclear whether proteinuria alone exhibits similar association with functional status regardless of CKD. No reports focus on this association using the severity of proteinuria among geriatric patients with acute medical illnesses.

Continue reading “Unusual life cycle and impact on microfibril assembly of ADAMTS17, a secreted metalloprotease mutated in genetic eye disease” »

Latest study on chronic kidney disease (CKD) as it relates to the elderly patients and the relationship to the elderly’s organ decline over time. I can most certainly attest that I have seen many patients in their final days/ hours seeing their kidneys shutdown as a final state of life. Key is hopefully what doctors find in this research will enable us to prevent kidney failure or even improve the synbio kidney product that is being experimented on today for dialysis patients who badly need transplants and have a hard time finding donors.

Elderly are frequently hospitalized due to their age-associated organ degeneration, the presence of co-morbidities, and their susceptibility to adverse insults. Alterations in functional status often occur during hospitalization, and the degree of functional decline can parallel the severity of illnesses. For older persons, gauging their pre-morbid and in-hospital functional status facilitates treatment planning and potentially functional restoration^1,2,3. While the identification of risk factors or markers of poor pre-morbid and in-hospital functional status may help facilitate this process, this area remains under-researched to date. Factors associated with functional decline in the hospitalized elderly include the types of morbidities and the reasons for their admission. Indeed, elderly with chronic kidney disease (CKD) are more likely to exhibit functional decline, beginning from the earlier stage of CKD to end-stage renal disease (ESRD)^4,5; functional dependency also predisposes individuals with CKD and ESRD to recurrent hospitalization and higher mortality.

Albuminuria and proteinuria, as the staging criteria for CKD in the most recent version of Kidney Disease Improving Global Outcomes (KDIGO) CKD guidelines, are both well-established predictors of subsequent renal function decline. There is increasing awareness that albuminuria and proteinuria have an independent role in the prediction of adverse outcomes apart from the baseline renal function. As explained above, although CKD is associated with poor functional status, it is still unclear whether proteinuria alone exhibits similar association with functional status regardless of CKD. No reports focus on this association using the severity of proteinuria among geriatric patients with acute medical illnesses.

Continue reading “Dipstick proteinuria level is significantly associated with pre-morbid and in-hospital functional status among hospitalized older adults: a preliminary study” »

This is definitely a share that is interesting to many studying synthetic organs and their acceptance into the human body as well as the work occurring on Quantum biology as well.

The goal of in vitro and in vivo toxicity testing is to identify compounds that would predict adverse reactions in humans. Olson et al. found that only 70% of human toxicity was predicted from animal testing. Currently we rely on traditional toxicity testing in animals, a 1930’s methodology that is now challenged due to questionable relevance to human risk, high cost, ethical concerns, and throughput that is too limited for the nearly 80,000 industrial chemicals not yet tested for safety. Additionally, testing usually extrapolates acute, high dose animal results to chronic, low dose human exposures, thereby risking rejection or limiting the use of drugs, industrial chemicals or consumer products. Moreover, the ability of lab animal target organ toxicity to predict dose-limiting toxicity in the corresponding human organ varies widely, from a low of 30% for human cutaneous toxicity, to 50–60% for human hepatotoxicity, to a high of 90% for hematological drug toxicity. Animal drug efficacy models are also notoriously discordant. In an analysis of six drugs to treat head injury, hemorrhage, acute ischemic stroke, neonatal respiratory distress syndrome, and osteoporosis, it was found that efficacy was similar in animals and humans for three drugs but was dissimilar for another three. In oncology drug development, animal models often over-predict anti-tumor efficacy in humans^3,4. Examples such as these highlight the need to continue research into methods that reduce the dependence on laboratory animals for toxicity testing of environmental chemicals, determine efficacy and toxicity in drug development, serve as a mimic of human diseases, and provide patient-specific guidance in the emerging field of precision medicine.

Recent advances in bioengineered materials, microfluidic technology, and the availability of human primary, immortalized, and induced pluripotent stem cell (iPSC)-derived cells are enabling development of human microphysiological systems (MPS), sometimes called “organs-on-a-chip” or “human-on-a-chip,” that use multiple organ-specific human cells to recapitulate many functional and structural properties of a human organ. It is now generally accepted and supported by data that cellular responses to drugs in most human organs are more accurately approximated in 3D cell cultures than in traditional static 2D cell cultures^5,6. Microfluidic perfusion further improves model performance by providing a flow of nutrients and oxygen and the removal of waste products from the cell cultures. Physiologically relevant flow increases oxygen consumption, Krebs cycle activity and secretion of synthesized proteins, and decreases expression of the hypoxia HIF1 gene. Flow also improves the absorption and metabolism of compounds like benzo[a]pyrene^6,8,9. The large number of recent publications reviewing organ MPS models indicates a high degree of interest by industrial and academic researchers, granting agencies and other stakeholders^10,11,12,13. In addition to the stand-alone MPS, investigators are linking MPS to study organ-organ functional interactions, efficacy, PK and toxicology^{14,15,16,17,18}.

Continue reading “Intestine, Liver, Kidney Proximal Tubule, Blood-Brain Barrier and Skeletal Muscle” »

Interesting read for those interested in inorganic protein (NP) states from a solid to a liquid as the research proves inorganic NPs are in a ‘glassy’ state while transitioning from a solid to a liquid form.

Molecular dynamics simulations of ubiquitin in water/glycerol solutions are used to test the suggestion by Karplus and coworkers that proteins in their biologically active state should exhibit a dynamics similar to ‘surface-melted’ inorganic nanoparticles (NPs). Motivated by recent studies indicating that surface-melted inorganic NPs are in a ‘glassy’ state that is an intermediate dynamical state between a solid and liquid, we probe the validity and significance of this proposed analogy. In particular, atomistic simulations of ubiquitin in solution based on CHARMM36 force field and pre-melted Ni NPs (Voter-Chen Embedded Atom Method potential) indicate a common dynamic heterogeneity, along with other features of glass-forming (GF) liquids such as collective atomic motion in the form of string -like atomic displacements, potential energy fluctuations and particle displacements with long range correlations (‘colored’ or ‘pink’ noise), and particle displacement events having a power law scaling in magnitude, as found in earthquakes. On the other hand, we find the dynamics of ubiquitin to be even more like a polycrystalline material in which the α-helix and β-sheet regions of the protein are similar to crystal grains so that the string -like collective atomic motion is concentrated in regions between the α-helix and β-sheet domains.

For fellow innovators and private scientists who dream and believe in your dream.

Rule 3: Their Ideas Look Like Failure In The Beginning

When innovators share what they’re working on early in the process, they open the floodgates to premature criticism. This is only natural considering that innovation stems from a singular vision that no one else sees yet.

Continue reading “Five Rules That Define The Technology Innovator” »

Nice.

Orbis Research Present’s Mid IR Sensors Market Shares, Strategies, and Forecasts, Worldwide to 2022 enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Report explores the Key Players, Industry Overview, Supply and Consumption Analysis to 2022.

With the work we are doing on cell circuitry technology and Quantum; these implants will become more and more seamless in all living things.

A biosensor developed in Clemson University, South Carolina, funded by the U.S. Department of Defense, will be able to transmit information regarding blood lactate and glucose levels of a wounded soldier or of other injured patients. The biochip will be implanted in the patient’s body for a short time and will wirelessly transmit the levels of lactate and glucose to the medical staff.

The biochip, sized 2mm x 4mm x 0.5mm, is a dual sensing element coated with hydrogels to prevent it from being rejected by human tissue. The sensor has the ability to transmit life saving readings to the medical personnel. The implantation of the chip will only be temporary, although long term biochip implants are also being tested and may be used as a precaution in some cases.

Continue reading “Implanted Biosensors Track Vital Signs” »

Nice.

Researchers at the University of Central Florida (UCF) in the US are combining nanoscience with the principle of Faraday rotation, a magnetic phenomenon discovered in 1845, in a new method for speedy medical tests.

The team applied the magneto-optical technique, called frequency-domain Faraday rotation spectroscopy—or fd-FRS, to characterize proteins, using antibody-functionalized magnetic nanoparticles (MNPs).

Continue reading “Faraday Rotation Spectroscopy for Speedy Medical Testing” »